Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

Eye (Basingstoke)

Volumn 26, Issue 7, 2012, Pages 1004-1011

  Lai, T Y Y ^a   Luk, F O J ^a   Lee, G K Y ^a   Lam, D S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

anti VEGF therapy; bevacizumab; choroidal neovascularization; high myopia; pathologic myopia; ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; EYE FUNDUS; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; PROGNOSIS; REFRACTION ERROR; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84863876595     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.97     Document Type: Article

References (36)

1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-1581. (Pubitemid 15197032)
2. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 2003; 87: 570-573. (Pubitemid 36535327)
3. Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 2002; 109: 712-719. (Pubitemid 34270128)
4. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010; 117: 1595-1611.
5. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003; 110: 667-673. (Pubitemid 36520061)
6. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005; 89: 1522-1528. (Pubitemid 41527394)
7. Coutinho AM, Silva RM, Nunes SG, Cachuio ML, Figueira JP, Murta JN. Photodynamic therapy in high myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina 2011; 31: 1089-1094.
8. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathologic myopia. Br J Ophthalmol 2007; 91: 157-160. (Pubitemid 46202862)
9. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165. (Pubitemid 46202863)
10. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114: 2190-2196.
11. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma- Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 707-712. (Pubitemid 47051766)
12. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008; 28: 1308-1313.
13. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol 2009; 93: 150-154.
14. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149: 140-146.
15. Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez- Ulla F, Silva R et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010; 30: 1609-1615.
16. Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D et al. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: oneyear results. Retina 2010; 30: 739-747.
17. Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina 2011; 31: 880-886.
18. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab: a randomized controlled trial. Am J Ophthalmol 2010; 149: 458-64.e1.
19. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 1117-1123.
20. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756.
21. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009; 23: 1275-1280.
22. Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010; 30: 399-406.
23. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30: 407-412.
24. Varano M, Tedeschi M, Oddone F, Perillo L, Coppe AM, Parravano M. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Retina 2010; 30: 413-417.
25. Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011; 118: 111-118.
26. Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161: e87-e93.
27. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010; 248: 937-941.
28. Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011; 25: 375-381.
29. Hayashi K, Shimada N, Moriyama M, Hayashi W, Tokoro T, Ohno-Matsui K. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012; 32: 687-695.
30. Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naïve myopic choroidal neovascularization. Retina 2012; 32: 949-955.
31. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol 2010; 94: 864-870.
32. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30: 418-424.
33. Kuo JZ, Ong FS, Yeung L, Wu WC, Chen YP, Wang NK et al. Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization. Retina 2011; 31: 1835-1840.
34. Shimada N, Ohno-Matsui K, Hayashi K, Yoshida T, Tokoro T, Mochizuki M. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011; 55: 378-382.
35. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710-718. (Pubitemid 46348374)
36. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 1062-1066.